Novel device eases instillation of eye drops

Article

Patients who used a proprietary eye drop delivery device (Eyedrop, Vanguard Design, São Paulo, Brazil) in a pilot study reported that it eased the instillation of hypotensive drops, especially if they weren’t used to using eye drops, the study authors report in the Journal of Clinical Ophthalmology.

Patients who used a proprietary eye drop delivery device (Eyedrop, Vanguard Design, São Paulo, Brazil) in a pilot study reported that it eased the instillation of hypotensive drops, especially if they weren’t used to using eye drops, the study authors report in the Journal of Clinical Ophthalmology. Use of the plastic device, into which the medication bottle is inserted, did not change the drops’ effectiveness nor the frequency of side effects.

“The improvement in patient adherence to treatment could result in better IOP control and lower risk of progression over time,” the authors wrote. “Further studies with larger sample sizes and longer follow-up are necessary in order to better investigate such aspects.”

The study included 32 patients, 44% of whom had glaucoma. No significant difference in mean IOP variation existed between those using the device and those not using it. Patients learned how to use the device via video and a handout that included written instructions and illustrations after initially using the device under physician supervision.

The researchers are from the United States and Brazil.

 

 

 

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.